Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 8INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Neoplasms 2875Carcinoma, Non-Small-Cell Lung 2428Breast Neoplasms 2068Colorectal Neoplasms 1247Neoplasm Metastasis 1232Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 758Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 436Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

imisopasem manganese 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Hypotension × Clear all
NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡